Price to Book Value (P/BV)
since 2005
Paying user area
Try for free
Amgen Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Amgen Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Amgen Inc., P/BV, long-term trends, calculation
| P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Stockholders’ equity1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2011 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 10, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Amgen Inc. Annual Report.
The price-to-book value (P/BV) ratio exhibits considerable fluctuation over the observed period, spanning from 2006 to 2026. Initially, the ratio demonstrates a gradual decline, followed by a period of increased volatility and, ultimately, a substantial increase in recent years.
- Initial Decline (2006-2009)
- From 2006 to 2009, the P/BV ratio decreased from 4.26 to 2.48. This decline occurred alongside fluctuations in both share price and book value per share (BVPS). While the share price experienced a decrease, the BVPS initially declined and then increased, suggesting the ratio’s movement was influenced by both factors.
- Period of Stability and Moderate Growth (2010-2014)
- Between 2010 and 2014, the P/BV ratio remained relatively stable, fluctuating between 2.04 and 4.30. BVPS generally increased during this period, while the share price also showed an upward trend. This suggests investor confidence was growing, reflected in a willingness to pay more for each dollar of book value.
- Significant Increase (2015-2023)
- From 2015 onwards, the P/BV ratio experienced a marked increase, rising from 3.94 to a peak of 35.01 in 2023. This surge coincided with a substantial increase in share price and, initially, a corresponding increase in BVPS. However, the dramatic rise in the ratio after 2019 suggests the share price grew at a significantly faster rate than BVPS, potentially indicating overvaluation or heightened market expectations.
- Recent Moderation (2024-2026)
- The most recent observations (2024-2026) indicate a slight moderation in the P/BV ratio, decreasing from 24.94 to 22.99. While the share price continues to increase, the BVPS also shows an upward trend, suggesting a potential stabilization of the valuation. The ratio remains significantly elevated compared to historical levels.
Overall, the P/BV ratio demonstrates a clear shift in investor sentiment over the period. The initial decline and subsequent stability suggest a period of measured growth, while the dramatic increase in recent years indicates a significant re-evaluation of the company’s worth by the market. The recent moderation may signal a correction or a more sustainable valuation level.
Comparison to Competitors
Amgen Inc., P/BV, long-term trends, comparison to competitors
| Amgen Inc. | AbbVie Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | ||||||||||||
| Feb 14, 2025 | ||||||||||||
| Feb 14, 2024 | ||||||||||||
| Feb 9, 2023 | ||||||||||||
| Feb 16, 2022 | ||||||||||||
| Feb 9, 2021 | ||||||||||||
| Feb 12, 2020 | ||||||||||||
| Feb 13, 2019 | ||||||||||||
| Feb 13, 2018 | ||||||||||||
| Feb 14, 2017 | ||||||||||||
| Feb 16, 2016 | ||||||||||||
| Feb 19, 2015 | ||||||||||||
| Feb 24, 2014 | ||||||||||||
| Feb 27, 2013 | ||||||||||||
| Feb 29, 2012 | ||||||||||||
| Feb 25, 2011 | ||||||||||||
| Mar 1, 2010 | ||||||||||||
| Feb 27, 2009 | ||||||||||||
| Feb 28, 2008 | ||||||||||||
| Feb 28, 2007 | ||||||||||||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Amgen Inc., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Amgen Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 13, 2026 | ||
| Feb 14, 2025 | ||
| Feb 14, 2024 | ||
| Feb 9, 2023 | ||
| Feb 16, 2022 | ||
| Feb 9, 2021 | ||
| Feb 12, 2020 | ||
| Feb 13, 2019 | ||
| Feb 13, 2018 | ||
| Feb 14, 2017 | ||
| Feb 16, 2016 | ||
| Feb 19, 2015 | ||
| Feb 24, 2014 | ||
| Feb 27, 2013 | ||
| Feb 29, 2012 | ||
| Feb 25, 2011 | ||
| Mar 1, 2010 | ||
| Feb 27, 2009 | ||
| Feb 28, 2008 | ||
| Feb 28, 2007 | ||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Amgen Inc., P/BV, long-term trends, comparison to industry (health care)
| Amgen Inc. | Health Care | |
|---|---|---|
| Feb 13, 2026 | ||
| Feb 14, 2025 | ||
| Feb 14, 2024 | ||
| Feb 9, 2023 | ||
| Feb 16, 2022 | ||
| Feb 9, 2021 | ||
| Feb 12, 2020 | ||
| Feb 13, 2019 | ||
| Feb 13, 2018 | ||
| Feb 14, 2017 | ||
| Feb 16, 2016 | ||
| Feb 19, 2015 | ||
| Feb 24, 2014 | ||
| Feb 27, 2013 | ||
| Feb 29, 2012 | ||
| Feb 25, 2011 | ||
| Mar 1, 2010 | ||
| Feb 27, 2009 | ||
| Feb 28, 2008 | ||
| Feb 28, 2007 | ||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).